Subscribe to Newsletter
Subspecialties Retina, Basic & Translational Research, Imaging & Diagnostics

Superparamagnetic-expialidocious

Credit: Image sourced from Unsplash.com

How great is it to accomplish two things at once? Personally, I try to defeat my multitasking demons by reading while using my exercise bike (assisted by a tablet stand – and preferably with a coffee in hand!). But when it comes to medicine, diagnosis and treatment are normally two separate entities and by no means as easy to juggle as my heart rate zone and the latest ophthalmology literature. Recently, however, the dichotomy of diagnosis and therapy is beginning to disappear thanks to theranostic technologies. If you think that “theranostic” sounds suspiciously like a mix of “therapy” and “diagnostics,” then you have earned your spoonful of sugar.

Researchers from the Second Affiliated Hospital of Chongqing Medical University in Chongqing, China, are using theranostics as a potential retinoblastoma treatment. They designed a nanoparticle drawn to the negative charge of cholesterol that accumulates in cancerous tissue; can be detected using ultrasound, photoacoustic, and magnetic resonance imaging techniques for diagnostic purposes; and also produces heat to kill cancer cells when targeted by activation of photothermal and photodynamic processes with a 808 nm laser(1). The nanoparticle itself is a folate and magnetic cationic nanoliposome that encapsulates two active components, indocyanine green and perfluorohexane.  In the lab, it targeted cancer cells with just over 95 percent cell uptake rate and, when used in mice, achieved almost complete tumor regression. The therapy was also deemed to be safe and have no off-target toxicities when tested in mice. This combined approach to therapy not only simplifies the treatment and synthesis processes, but also lowers manufacturing costs.

The results offer promising evidence that these nanoparticles could be used for diagnosis and treatment of retinoblastoma – but, on a wider scale, they’re another checkmark in the column of superparamagnetic theranostics as an efficient cancer treatment option in many tissues. Hopefully, this medicine won’t require a spoonful of sugar to help it go down in a most delightful way!
 

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. W Zheng et al., Int J Nanomedicine, 17, 3217 (2022). PMID: 35924259.
About the Author
Geoffrey Potjewyd

Associate Editor, The Ophthalmologist

The lion’s share of my PhD was spent in the lab, and though I mostly enjoyed it (mostly), what I particularly liked was the opportunity to learn about the latest breakthroughs in research. Communicating science to a wider audience allows me to scratch that itch without working all week only to find my stem cell culture has given up the ghost on the Friday (I’m not bitter). Fortunately for me, it turns out writing is actually fun – so by working for Texere I get to do it every day, whilst still being an active member of the clinical and research community.

Related Product Profiles
Uncover the Unique DNA of SPECTRALIS®

| Contributed by Heidelberg Engineering

Subspecialties Retina
ForeseeHome® – remote monitoring to help detect wet AMD earlier and improve outcomes

| Contributed by Notal Vision

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: